Fate Therapeutics Inc FATE shares are trading higher on Friday, after a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer.
The company will receive $50 million upfront, $50 million in equity investment and is eligible to receive up to $1.8 billion.
Fate Therapeutics shares traded up 11.01% to $23.39 on Friday. The stock has a 52-week high of $32.39 and a 52-week low of $12.59 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in